{"id":4801,"date":"2012-03-06T12:55:44","date_gmt":"2012-03-06T22:55:44","guid":{"rendered":"http:\/\/www.hawaii.edu\/news\/?p=4801"},"modified":"2021-04-23T15:16:50","modified_gmt":"2021-04-24T01:16:50","slug":"pono-corporation","status":"publish","type":"post","link":"https:\/\/www.hawaii.edu\/news\/2012\/03\/06\/pono-corporation\/","title":{"rendered":"UH<\/abbr> technology will be commercialized"},"content":{"rendered":"Reading time: <\/span> 2<\/span> minutes<\/span><\/span>
\"Dr.
Technologies developed by André Bachmann and other UH<\/abbr> researchers will be commercialized by Honolulu-based Pono Corporation.<\/figcaption><\/figure>\n

Three technologies developed by the University of Â鶹´«Ã½<\/span><\/a> are now owned by Honolulu-based Pono Corporation under an agreement that will allow UH<\/abbr> to realize the value of the technologies sooner than it would with a traditional licensing deal due to long drug development timelines.<\/p>\n

Under the terms of a technology commercialization agreement signed by the university’s Office of Technology Transfer and Economic Development<\/a> with Pono, the university receives equity stake in the company and is now a shareholder in Pono in exchange for an assignment of the technologies.<\/p>\n

“We are evolving our technology transfer process to speed commercialization of early-stage technologies developed at the University of Â鶹´«Ã½<\/span>,” said UH<\/abbr> President M.R.C. Greenwood<\/strong>. “The agreement with Pono will allow the university to participate side-by-side with other Pono shareholders and founders as technology developed at the University of Â鶹´«Ã½<\/span> is commercialized.”<\/p>\n

The agreement gives Pono ownership of three UH<\/abbr>-developed technologies, including a proteasome inhibitor drug, humanized cobra venom factor, and a hybrid nanocarrier drug delivery system.<\/p>\n

“Pono is honored to have the opportunity to build on the work done at the University of Â鶹´«Ã½<\/span> by moving forward with the commercialization of these technologies,” said Kaleo Taft, Pono’s chief technology officer.<\/p>\n

Pono will work to develop the technologies under the agreement with a focus on moving them through the regulatory approval process.<\/p>\n

“We are looking forward to this promising opportunity to work with the company towards the clinical development of our novel anti-cancer drugs,” said André S. Bachmann<\/strong>, associate professor and chairman of the Department of Pharmaceutical Sciences at the UH<\/abbr> Hilo College of Pharmacy<\/a>.<\/p>\n

Bachmann is one of the inventors of the proteasome inhibitor discovery and a co-inventor of the nanocarrier drug delivery system with Mahavir Chougule<\/strong>, assistant professor at the UH<\/abbr> Hilo College of Pharmacy.<\/p>\n

About the technologies<\/h2>\n

The proteasome inhibitors discovered by Bachmann and his collaborators are a new class of compounds potentially useful for anti-cancer and other therapeutic uses. The proprietary nanocarrier system developed by Bachmann and Chougule aims to provide improved cancer treatment through targeted, tumor-specific delivery of chemotherapeutic drugs.<\/p>\n

Read the article in the April 2010 issue of Mālamalama<\/em><\/a> featuring Bachmann’s research.<\/p>\n

At the University of Â鶹´«Ã½<\/span> Cancer Center<\/a>, Carl-Wilhelm Vogel<\/strong> and David Fritzinger<\/strong> developed the cobra venom factor proteins, which are modified for treatment of diseases such as reperfusion injury and autoimmune diseases.<\/p>\n","protected":false},"excerpt":{"rendered":"

Three technologies developed by UH<\/abbr> researchers will be commercialized by the Honolulu-based Pono Corporation.<\/p>\n","protected":false},"author":16,"featured_media":4941,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30],"tags":[52,169,14,9,947],"class_list":["post-4801","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research","tag-college-of-pharmacy","tag-uh-cancer-center","tag-uh-hilo","tag-uh-manoa","tag-uh-system","entry","has-media"],"aioseo_notices":[],"jetpack_featured_media_url":"https:\/\/www.hawaii.edu\/news\/wp-content\/uploads\/2012\/03\/bachman-f.jpg","_links":{"self":[{"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/posts\/4801","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/comments?post=4801"}],"version-history":[{"count":24,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/posts\/4801\/revisions"}],"predecessor-version":[{"id":140126,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/posts\/4801\/revisions\/140126"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/media\/4941"}],"wp:attachment":[{"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/media?parent=4801"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/categories?post=4801"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hawaii.edu\/news\/wp-json\/wp\/v2\/tags?post=4801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}